Down 8.7% today, more than its biotech peers' 1.4%; no story names it yet.
Fell on Nov 9
Down 5% on Nov 9 while the S&P 500 rose 2%.
−3Long-term trend
TNXP's Quality Score fell 2 points on Tue, Nov 10, to -7. Trading went back to normal after a busy day.
Follow TNXP's trial news. Pro members can get an alert when Tonix Pharmaceuticals Holding files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 106.7% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
After its last 4 reports it closed -1.9% on average, higher 1 of 4 times.
About 3 quarters
CEO Seth Lederman bought 2,000 shares on Aug 27. 6 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
TNXP is #244 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 244 |
Expected to report Thu Mar 11, before the open (in 121 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase of $16.5 million was primarily attributable to higher manufacturing expenses of $9.8 million, clinical expenses of $3.6 million and non-clinical expenses of $1.1 million as the Company advanced its prioritized pipeline, as well as higher employee-related costs of $1.5 million due to increased headcount.”
TNXP's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $19.9 million was primarily attributable to higher sales and marketing expenses of $13.5 million, employee-related expenses of $4.1 million, and professional expenses of $1.5 million.”
From its results filing (SEC filing · Nov 9)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -13.4% | -5.3% | not yet |
| Aug 10, 2026 | -3.4% | +4.7% | +5.7% |
| May 11, 2026 | -9.4% | -5.9% | +1.1% |
Sales grew every year from 2023 to 2025, to $13.1M. It lost money in each of the three years.
RSI 16.1, MACD above signal, below both averages. Not scored.
4 insiders bought $172K across 5 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: TNXP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
TNXP scores -7 today, which Breakaway calls Poor. It is #244 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 5% on Nov 9 while the S&P 500 rose 2%. Cash lasts about 3 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TNXP scores -7 today, which Breakaway calls Poor (below zero). That is #244 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TNXP's -7.
4 insiders bought $172K across 5 filings in the last 6 months. No open-market sales on record. The newest is Seth Lederman, Chief Executive Officer, who bought $28K on Aug 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.